Takeda Pharmaceutical Co Stock EBITDA
| TAK Stock | USD 13.33 0.04 0.30% |
Takeda Pharmaceutical Co fundamentals help investors to digest information that contributes to Takeda Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Takeda Stock. The fundamental analysis module provides a way to measure Takeda Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Takeda Pharmaceutical stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | 900.3 B | 587.4 B |
Takeda | EBITDA |
Takeda Pharmaceutical Co Company EBITDA Analysis
Takeda Pharmaceutical's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Takeda Pharmaceutical EBITDA | 900.33 B |
Most of Takeda Pharmaceutical's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Takeda Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Takeda EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Takeda Pharmaceutical is extremely important. It helps to project a fair market value of Takeda Stock properly, considering its historical fundamentals such as EBITDA. Since Takeda Pharmaceutical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Takeda Pharmaceutical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Takeda Pharmaceutical's interrelated accounts and indicators.
Click cells to compare fundamentals
Takeda EBITDA Historical Pattern
Today, most investors in Takeda Pharmaceutical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Takeda Pharmaceutical's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's ebitda growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Takeda Pharmaceutical ebitda as a starting point in their analysis.
Takeda Pharmaceutical EBITDA |
| Timeline |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Takeda Ebitda
Ebitda |
|
According to the company disclosure, Takeda Pharmaceutical Co reported earnings before interest,tax, depreciation and amortization of 900.33 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The ebitda for all United States stocks is significantly lower than that of the firm.
Takeda EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Takeda Pharmaceutical's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Takeda Pharmaceutical could also be used in its relative valuation, which is a method of valuing Takeda Pharmaceutical by comparing valuation metrics of similar companies.Takeda Pharmaceutical is currently under evaluation in ebitda category among its peers.
Takeda Pharmaceutical Current Valuation Drivers
We derive many important indicators used in calculating different scores of Takeda Pharmaceutical from analyzing Takeda Pharmaceutical's financial statements. These drivers represent accounts that assess Takeda Pharmaceutical's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Takeda Pharmaceutical's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.5T | 3.2T | 2.7T | 3.4T | 3.3T | 4.6T | |
| Enterprise Value | 7.0T | 6.8T | 6.2T | 7.2T | 8.5T | 9.0T |
Takeda Pharmaceutical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Takeda Pharmaceutical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Takeda Pharmaceutical's managers, analysts, and investors.Environmental | Governance | Social |
Takeda Pharmaceutical Institutional Holders
Institutional Holdings refers to the ownership stake in Takeda Pharmaceutical that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Takeda Pharmaceutical's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Takeda Pharmaceutical's value.| Shares | Managed Asset Portfolios, Llc | 2024-09-30 | 1.6 M | Envestnet Asset Management Inc | 2024-06-30 | 1.5 M | Blackrock Inc | 2024-06-30 | 1.4 M | Causeway Capital Management Llc | 2024-09-30 | 1.3 M | Macquarie Group Ltd | 2024-06-30 | 1 M | Wells Fargo & Co | 2024-06-30 | 871.7 K | Bank Of America Corp | 2024-06-30 | 867.1 K | Jane Street Group Llc | 2024-06-30 | 603.8 K | Kayne Anderson Rudnick Investment Management Llc | 2024-06-30 | 585.8 K | Capital Research Global Investors | 2024-09-30 | 13.1 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 10 M |
Takeda Fundamentals
| Return On Equity | 0.0415 | ||||
| Return On Asset | 0.0278 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 69.63 B | ||||
| Shares Outstanding | 3.17 B | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 2.44 % | ||||
| Number Of Shares Shorted | 6.03 M | ||||
| Price To Earning | 27.57 X | ||||
| Price To Book | 0.94 X | ||||
| Price To Sales | 0.01 X | ||||
| Revenue | 4.26 T | ||||
| Gross Profit | 2.44 T | ||||
| EBITDA | 900.33 B | ||||
| Net Income | 144.07 B | ||||
| Cash And Equivalents | 533.53 B | ||||
| Cash Per Share | 208.91 X | ||||
| Total Debt | 5.46 T | ||||
| Debt To Equity | 0.81 % | ||||
| Current Ratio | 1.18 X | ||||
| Book Value Per Share | 4,366 X | ||||
| Cash Flow From Operations | 716.34 B | ||||
| Short Ratio | 3.61 X | ||||
| Earnings Per Share | 0.59 X | ||||
| Price To Earnings To Growth | 0.70 X | ||||
| Target Price | 2481.07 | ||||
| Number Of Employees | 49.28 K | ||||
| Beta | 0.46 | ||||
| Market Capitalization | 42.18 B | ||||
| Total Asset | 15.11 T | ||||
| Retained Earnings | 1.39 T | ||||
| Working Capital | 245.48 B | ||||
| Annual Yield | 0.04 % | ||||
| Five Year Return | 4.54 % | ||||
| Net Asset | 15.11 T | ||||
| Last Dividend Paid | 192.0 |
About Takeda Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Takeda Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Takeda Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Takeda Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Takeda Pharmaceutical Piotroski F Score and Takeda Pharmaceutical Altman Z Score analysis. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.049 | Dividend Share 192 | Earnings Share 0.59 | Revenue Per Share 1.4 K | Quarterly Revenue Growth 0.127 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.